Overview
FOXO4-DRI is a D-retro-inverso (DRI) peptide specifically designed to disrupt the interaction between FOXO4 (forkhead box O4) and p53, a molecular interaction that enables senescent cells to evade apoptosis and persist in tissues. Developed by Dr. Peter de Keizer at Erasmus University Medical Center in the Netherlands, FOXO4-DRI represents one of the first rationally designed senolytic agents—compounds that selectively eliminate senescent cells while sparing healthy cells.
Cellular senescence is now recognized as one of the hallmarks of aging. Senescent cells accumulate with age and secrete a pro-inflammatory cocktail known as the senescence-associated secretory phenotype (SASP), which drives chronic inflammation, tissue dysfunction, and age-related disease. By selectively eliminating these cells, senolytic therapies aim to restore tissue function and reverse aspects of aging.
In the landmark 2017 study published in Cell, de Keizer demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells both in vitro and in naturally aged mice. Treated mice showed restoration of fur density, improved renal function, and increased fitness. These results represented some of the most compelling evidence for cellular rejuvenation through targeted senescent cell clearance.
FOXO4-DRI remains a research-stage compound with no human clinical trials. Its large size (48 amino acids), high cost of synthesis, and limited pharmacokinetic data present significant challenges for clinical translation, though the proof-of-concept has inspired broader senolytic drug development.
Quick facts
- Mechanism
- DRI peptide disrupting FOXO4-p53 to selectively kill senescent cells
- Primary use
- Senolytic Therapy & Anti-Aging
- Evidence
- limited
- FDA
- Not approved
- Route
- Intravenous or intraperitoneal injection (research)
- Typical results
- Selective senescent cell clearance and tissue rejuvenation demonstrated in aged mice
Chemical information
FOXO4-DRI (C₂₂₈H₄₈₈N₈₆O₆₄) is a longevity compound with a molecular weight of 5358.06 g/mol. Its structural characteristics underpin its biological activity in longevity and anti-aging research.
How FOXO4-DRI works
FOXO4-DRI exploits a specific survival mechanism unique to senescent cells. In senescent cells, FOXO4 sequesters p53 in PML (promyelocytic leukemia) nuclear bodies, preventing p53 from triggering apoptosis. This FOXO4-p53 interaction is what allows senescent cells to resist the self-destruction signals that would normally eliminate damaged cells. FOXO4-DRI competitively disrupts this interaction by binding to p53, freeing it to activate the intrinsic apoptotic pathway selectively in senescent cells.
The D-retro-inverso design is crucial to FOXO4-DRI's function. By using D-amino acids in a reversed sequence, the peptide maintains the same side-chain topology as the natural L-peptide but gains resistance to protease degradation and enhanced cell-penetrating properties. The DRI approach results in a peptide that is biologically active but metabolically stable—critical for a therapeutic that must reach intranuclear targets.
The selectivity of FOXO4-DRI for senescent cells over healthy cells is its most important feature. In healthy cells, p53 is regulated through multiple mechanisms (MDM2-mediated degradation, cytoplasmic sequestration) and is not dependent on FOXO4 for survival. Therefore, disrupting the FOXO4-p53 interaction has minimal effect on healthy cells but triggers catastrophic apoptotic signaling in senescent cells that rely on this specific survival mechanism.
When FOXO4-DRI releases p53 from FOXO4 sequestration in senescent cells, p53 activates its canonical apoptotic program: upregulating pro-apoptotic BCL-2 family members (BAX, BAK), triggering mitochondrial outer membrane permeabilization, cytochrome c release, and caspase cascade activation. The result is selective elimination of senescent cells through their own intrinsic apoptotic machinery.
- FOXO4-p53 disruption: Competitively disrupts the interaction that prevents senescent cell apoptosis
- Senescent cell selectivity: Healthy cells are unaffected because they don't rely on FOXO4-p53 for survival
- D-retro-inverso stability: D-amino acid design provides protease resistance and cell penetration
- p53 liberation: Freed p53 activates intrinsic apoptotic pathway (BAX/BAK, caspases)
- SASP reduction: Eliminating senescent cells reduces pro-inflammatory secretory phenotype
- Tissue rejuvenation: Cleared senescent niches allow healthy progenitor cell repopulation
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular weight | 5,358 g/mol | Large peptide; potential challenges for tissue distribution |
| Stability | Protease-resistant (DRI) | D-amino acid design provides exceptional metabolic stability |
| Administration (mice) | IP injection, 5 mg/kg | Translating mouse doses to humans is speculative |
| Treatment protocol (mice) | 3x/week for 3 weeks | Intermittent dosing allows for selective cell clearance |
| Onset of effects (mice) | 2–4 weeks | Tissue rejuvenation observed after senescent cell clearance period |
Dosing & administration
FOXO4-DRI dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for FOXO4-DRI is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • No human safety data available
- • Transient weight loss observed in mouse studies
- • Temporary diarrhea (noted in animal studies)
- • Injection site reactions (assumed for large peptide)
Serious / potential risks
- • No formal toxicology data in humans
- • Theoretical risk of excessive senescent cell clearance disrupting tissue homeostasis
- • Potential wound healing impairment (senescent cells play roles in wound repair)
- • Unknown effects on immune senescence and immunosurveillance
- • Large peptide with potential for immunogenic reactions
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Chemotherapy agents | Chemotherapy induces therapy-induced senescence; FOXO4-DRI could enhance clearance | Potential adjunctive use; active preclinical research area |
| Immunosuppressants | Senescent cell clearance involves immune system; immunosuppression may reduce efficacy | Theoretical concern; no clinical data |
| Other senolytics (dasatinib+quercetin) | Different senolytic mechanisms; potential additive senescent cell clearance | Combination approaches are being researched but not validated |
| Wound healing therapies | Senescent cells contribute to normal wound healing | Avoid during active wound healing or post-surgery |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Custom peptide synthesis | $500–$2,000+ per course | 48-amino acid DRI peptide is expensive to synthesize |
| Research suppliers | $300–$800 per 5mg | Limited availability; verify purity with mass spectrometry |
The bottom line
FOXO4-DRI is a groundbreaking proof-of-concept senolytic peptide that demonstrated selective senescent cell clearance and tissue rejuvenation in aged mice. While the science is compelling, the compound remains pre-clinical with no human trials, significant cost barriers, and unanswered questions about long-term safety of senescent cell elimination.
Best for
- • Longevity researchers studying senescence and senolytics
- • Academic investigation of FOXO4-p53 biology
- • Preclinical research into aging reversal mechanisms
Not for
- • Human self-experimentation (no safety data)
- • Individuals with active wounds or recovering from surgery
- • Those seeking cost-effective anti-aging interventions
- • Anyone without thorough understanding of senescence biology
Related compounds
Epitalon
Telomerase-activating anti-aging peptide targeting different hallmark of aging
SS-31
Mitochondria-targeted peptide addressing cellular energy decline in aging
Humanin
Mitochondrial-derived cytoprotective peptide with anti-aging properties
NAD+
Essential coenzyme addressing metabolic decline in aging
Frequently asked questions
References
- [1] Baar MP, Brandt RMC, Putavet DA, et al.. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell (2017). doi: 10.1016/j.cell.2017.02.031 PMID: 28340339
- [2] de Keizer PLJ.. The Fountain of Youth by Targeting Senescent Cells?. Trends Mol Med (2017). doi: 10.1016/j.molmed.2016.11.006 PMID: 28089481
- [3] Baker DJ, Childs BG, Durik M, et al.. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature (2016). doi: 10.1038/nature16932 PMID: 26840489
- [4] Kirkland JL, Tchkonia T.. Senolytic drugs: from discovery to translation. J Intern Med (2020). doi: 10.1111/joim.13141 PMID: 32686219
- [5] van Deursen JM.. The role of senescent cells in ageing. Nature (2014). doi: 10.1038/nature13193 PMID: 24828040